Designing next-generation drug development in precision medicine

International Conference on Pharmaceutical Chemistry

September 05-07, 2016 Frankfurt, Germany

Dimitrios H Roukos

Ioannina University, Greece

Posters & Accepted Abstracts: Med chem

Abstract :

Breakthrough next-generation sequencing (NGS) systems and computational network methods shape two main strategies in drugs-discovery design. First, based on spatiotemporal genomic clones evolution, novel targetable drugs can be discovered against genome-wide alterations. Primary tumor multiregional NGS analysis before and after neoadjuvant treatment can reveal both intratumor heterogeneity (ITH) and clonal evolution in response to this systemic treatment. Moreover, an innovative noninvasive method of repeated circulating cell-free tumor DNA (ctDNA) followed NGS (ctDNA-NGS) can reveal subclones of plasma levels at different time points. This monitoring of these patients can not only predict therapeutic resistance-based metastatic relapse but also can result in novel drugs development to prevent with high precision metastatic progression. Ultimately, comparison of ITH with ctDNA-NGS in future rationally designed clinical trial opens new horizons of comprehensive intrapatient heterogeneity (IPH) identification that could substantially improve tumor responsiveness and overall survival. Second, in a more distant future, approach understanding of noncoding genome variation and functionality along with exploitation of transcriptional networks, drive the future development of highly effective drugs disrupting deregulated cancer transcriptional biocircuits. Although this ENCODE project� based research direction reflects the pragmatic molecular interaction networks underlying critical biological processes; much more work and time is required for understanding how structural and functional genome changes are underlying therapeutic resistance and relapse. This speech is concentrated on these two main drugs-development strategies. The first one continues to be based on simple, single-gene linear transcription dogma agents. The second innovative highly complex transcriptional networks-based approach aims to the future discovery of drugs disrupting aberrant cancer transcriptional biocircuits.

Biography :

Email: droukos@uoi.gr